Market Research Store

HER-2 Positive Breast Cancer Market 2015 Review, Research, Trends, Industry Size, Share and Forecast 2019

Global HER-2 Positive Breast Cancer market to grow at a CAGR of 9.90% over the period 2014-2019


Deerfield Beach, FL -- (SBWIRE) -- 08/21/2015 -- Global HER-2 Positive Breast Cancer market to grow at a CAGR of 9.90% over the period 2014-2019. Breast cancer is characterized by uncontrolled growth of cancerous cells in the breast. It occurs in both males and females, however, the incidence of breast cancer in males is rare. Histologically, breast cancer can be classified into ductal carcinoma, lobular carcinoma, nipple cancer, and other undifferentiated carcinoma. Breast cancer is the second most common form of cancer in women. HER-2 is a protein that affects the growth of malignant cells and is usually found on the surface of normal breast cells. Sometimes, a large number of HER-2 receptors are found on the surface of breast cancer cells. These HER-2 receptors are responsible for stimulating the growth and division of malignant cancerous cells.

This condition is therefore known as HER-2 positive breast cancer. HER-2 positive breast cancers have a tendency to spread and metastasize more rapidly than HER-2 negative breast cancers. HER-2 positive breast cancer is more prevalent in females than males. In 2012, GLOBOCAN reported that breast cancer accounted for 11.9 percent of the total number of cancer cases and led to 522,000 deaths worldwide. HER-2 positive breast cancer accounts for almost 25 percent of all types of breast cancer.

Request For Research Report Sample @

The increase in prevalence of breast cancer resulting in a high rate of patient admissions, opting for the treatment regimen is a key driver of the market. The increase in urbanization, high life expectancy, and sedentary lifestyle has increased incidences of breast cancer. Unmet medical needs for safer drugs is another major driver of the market. Overall, the market is expected to grow at a CAGR of 9.90 percent during the forecast period of 2014-2019.

According to a 2014 publication by F. Hoffmann-La Roche, about 1.6 million incidences of breast cancer have been reported worldwide, with a mortality rate of 50,000 per annum due to HER-2 positive breast cancer. HER-2 positive breast cancer is diagnosed by measuring the level of HER-2 protein in the cancer cells. A sample of the tissue is collected from the breast using a biopsy, and the levels of HER-2 protein are checked.

"In the past decade, various targeted therapies have been introduced in the market for the treatment of breast cancer. These therapies cause fewer side effects than conventional chemotherapies. Drugs such as Herceptin and Kadcyla that target HER-2 receptors can be administered to patients as monotherapy or in combination,".

Enquiry Before Buying @

Covered in this Report

This report covers the present scenario and the growth prospects of the Global HER-2 Positive Breast Cancer Market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of targeted therapeutic agents, chemotherapeutic agents, and hormonal therapies that are used in the management of HER-2 positive breast cancer patients.

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global HER-2 Positive Breast Cancer market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

Access Full Industry Report @

Global HER-2 Positive Breast Cancer Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global HER-2 Positive Breast Cancer market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

"Combination therapies, which target distinct mechanisms, have become highly efficient in treating the disease. Targeting multiple pathways might also reduce the risk of developing treatment-resistant cancers."

To define the market conditions in the next 3-4 years, Our analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.